

Shoalhaven Cancer Care Centre June 2024

ISLHD CANCER CLINICAL TRIALS UNIT

Shoalhaven Cancer Care
Centre

Shoalhaven District Memorial Hospital

Corner of Scenic Drive &
North Street
Nowra NSW 2541

Ph: 02 4253 4384

Fax: 02 4222 5085

Email: ISLHD-CancerClinicalTrials@health. nsw.gov.au The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.


Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Colorectal cancer
- Skin cancer
- Gynaecological neoplasms
- Multiple Myeloma

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD
Trials Clinician, please phone the Shoalhaven
Cancer Care Centre on
02 4428 7400



ISLHD Clinical Trials **CURRENTLY OPEN FOR RECRUITMENT**

Scan the QR Code for more information including eligibility criteria

GI/Biliary

OXTOX: Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study.

Prof Chantrill *Satellite site

Closing soon

PARAGON-II: Phase II basket study of an ARomatase Gynae

> inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms. **Cohorts A, B, D, E, F (limited spots) only**

Dr Kasherman *Satellite site



Skin

CPOST: A randomised, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.

A/Prof Brungs *Satellite site



Multiple

CA057-001: A Phase 3, Two-Stage, Randomized, Multi-Myeloma center, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide. Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) **Part 2 now open for enrolment**

Dr Parmar *Satellite site



For further information regarding these trials at the Shoalhaven Cancer Care Centre you may also contact the trial coordinators as listed or email ISLHD-SCCC-CancerClinicalTrials@health.nsw.gov.au

Trial Coordinator	Availability	Contact details
Kyrie Rodgers	Mon-Thurs	02 4428 7516
Rachael Dunster	Tues, Thurs, Fri	02 4429 1676
Jamie Tomlinson [maternity leave from Nov 2023]	Wed-Fri	02 4429 1676